{
  "id": 7960928,
  "title": "Business : QurCan, Lilly Ink Research Deal For CNS, PNS Genetic Medicines",
  "url": "https://urgent.news/2026/09/17/business-qurcan-lilly-ink-research-deal-for-cns-pns-genetic-medicines",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T03:58:42.000Z",
  "source": {
    "name": "Bernama",
    "slug": "bernama",
    "url": "http://www.bernama.com/en/news.php?id=2608372"
  },
  "original_language": "en",
  "account": null,
  "summary": "KUALA LUMPUR, Sept 17 (Bernama) -- QurCan Therapeutics (QurCan), a Toronto-based biotechnology company, has announced an exclusive research and collaboration agreement with Eli Lilly and Company (Lilly) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}